Johnson & Johnson
JNJ
257.42
+3.63
+1.43%
Johnson & Johnson
US · JNJ
#25 by market cap
Listed 1970
257.42
+3.63
+1.43%
Live - 5344 symbols - heartbeat 296s ago
· 2026-10-20 09:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 16 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 76.38% -0.09pp
- Institutions
- 5,279 -16
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund62.57%
Public Company4.79%
Private Company3.39%
Government Pension Fund2.04%
Sovereign Wealth Fund1.41%
Hedge Fund0.93%
Family Office/Trust0.50%
Insurance Company0.35%
Government0.12%
VC/PE Fund0.14%
Other23.88%
Top holders as of 2026-06-30
BlackRock
8.80% · 212.10M sh
Vanguard Capital Management, LLC
7.09% · 170.74M sh
State Street Global Advisors
5.55% · 133.78M sh
Vanguard Portfolio Management, LLC
2.67% · 64.37M sh
Geode Capital Management, LLC
2.45% · 59.09M sh
Other
73.44%
J.P. Morgan Asset Management, Inc.
1.86% · 44.73M sh
Norges Bank Investment Management
1.32% · 31.83M sh
State Farm Mutual Automobile Insurance Company
1.31% · 31.59M sh
UBS Asset Management
1.22% · 29.45M sh
Northern Trust Global Investments
1.19% · 28.79M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Joaquin Duato | Chairperson & CEO | 0.01% |
| Jennifer Taubert | Executive VP & Worldwide Chairman of Pharmaceuticals | 0.01% |
| Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | 0.00% |
| Joseph Wolk | Chief Financial Officer | 0.00% |
| Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 0.00% |
| James Swanson | Executive Vice President | 0.00% |
| John Reed | Executive Vice President of Pharmaceuticals, R&D | 0.00% |
| Robert Decker | Controller & Chief Accounting Officer | 0.00% |
| Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | 0.00% |
| Kristen Mulholland | Head of Human Resources of Global Total Rewards | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +180 | -- |
| 2026-09-07 | Eugene Woods | Independent Director | Other Derivative Acquisition | +135 | -- |
| 2026-09-07 | Daniel Pinto | Director | Other Derivative Acquisition | +113 | -- |
| 2026-09-01 | Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | Derivative Exercise and Sale | -33,597 | $131.94–274.74 |
| 2026-08-31 | Tom Cavanaugh | Executive VP & Worldwide Chairman of Innovative Medicine | Initial Statement of Beneficial | 0 | -- |
| 2026-08-16 | Jennifer Taubert | Former Executive VP & Worldwide Chairman of Innovative Medicine | Derivative Exercise and Sale | -15,000 | $115.67–263.36 |
| 2026-08-12 | Joaquin Duato | Chairperson & CEO | Derivative Exercise and Sale | -123,291 | $115.67–262.00 |
| 2026-08-05 | Elizabeth Forminard | Chief Legal Officer | Open Market Disposition | -6,574 | $255.93 |
| 2026-08-05 | Elizabeth Forminard | Chief Legal Officer | Derivative Exercise and Sale | -9,344 | $131.94–257.76 |
| 2026-08-04 | Joaquin Duato | Chairperson & CEO | Open Market Disposition | -48,480 | $258.06–258.74 |
| 2026-07-19 | Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | Derivative Exercise and Sale | -23,054 | $129.51–251.27 |
| 2026-06-10 | Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | Derivative Exercise and Sale | -10,000 | $115.67–241.15 |
| 2026-06-08 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +214 | -- |
| 2026-06-08 | Eugene Woods | Independent Director | Other Derivative Acquisition | +161 | -- |
| 2026-06-08 | Daniel Pinto | Director | Other Derivative Acquisition | +134 | -- |
| 2026-04-30 | John Reed | Executive Vice President of Innovative Medicine and R&D | Derivative Exercise and Sale | -11,002 | $229.85 |
| 2026-04-30 | John Reed | Executive Vice President of Innovative Medicine and R&D | Derivative Exercise and Retained | +14,253 | -- |
| 2026-04-22 | John Morikis | Director | Other Derivative Acquisition | +1,540 | -- |
| 2026-04-22 | Hubert Joly | Independent Director | Other Derivative Acquisition | +975 | -- |
| 2026-04-22 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +975 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 09:30:11 · For reference only, not investment advice and not tailored to your situation.
talc litigation headlines still spook this stock every few months but the pharma pipeline keeps quietly delivering. slow and steady, exactly how I like my healthcare names.